Loading clinical trials...
Loading clinical trials...
The investigators will utilize a systematic approach for the diagnostic evaluation of patients to identify characteristics which may distinguish between Primary Immunodeficiency (PID) disorders versus Primary Ciliary Dyskinesia (PCD).
This protocol utilizes a cross-sectional study design. Over a 5-year period, the investigators will enroll patients who have clinical and lab features characteristic of a PID disorder or PCD, but do not have a confirmed genetic diagnosis. Innovative, standardized methods (SOPs) will be utilized, including ciliary ultrastructural analyses by transmission electron microscopy (TEM), as pertinent. Measures of nasal nitric oxide (nNO) will be performed in all subjects to allow comparisons of nNO values in PID vs. PCD. Patients with high likelihood of a PID disorder or a high likelihood of PCD will initially undergo research genetic testing on a commercial approved panel for PID disorders or a panel of at least 37 PCD genes. All subjects who do not have a genetic diagnosis from the test panels will undergo whole exome sequencing (WES) to search for novel genetic etiologies for PID or PCD.
Age
5 - 45 years
Sex
ALL
Healthy Volunteers
No
Stanford University
Palo Alto, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
National Heart, Lung and Blood Institute
Bethesda, Maryland, United States
Washington University in St. Louis
St Louis, Missouri, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Seattle Children's Hospital
Seattle, Washington, United States
The Hospital for Sick Children
Toronto, Ontario, Canada
McGill University
Montreal, Quebec, Canada
Start Date
December 1, 2020
Primary Completion Date
August 6, 2025
Completion Date
August 6, 2025
Last Updated
August 21, 2025
436
ACTUAL participants
Genetic Testing for PCD or PID
DIAGNOSTIC_TEST
Unaffected Family Member Genetic Testing
OTHER
Lead Sponsor
University of North Carolina, Chapel Hill
Collaborators
NCT07274631
NCT03266627
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions